Plasma Renin Activity: Which Tests to Order Alongside

Plasma renin activity (PRA) is a blood test that measures how fast a patient's plasma converts angiotensinogen into angiotensin I, reported in nanograms of angiotensin I generated per milliliter per hour (ng/mL/hr). It is a different assay from direct renin concentration (DRC), which measures renin protein mass by immunoassay rather than enzymatic rate, and either method can be used for aldosterone-to-renin ratio (ARR) screening as long as the laboratory has validated its own cutoff. On its own, a PRA value is close to uninterpretable. The useful clinical question is not "what is my renin level" but which paired tests, and which pre-analytic conditions, turn that single number into a diagnosis.

What plasma renin activity actually measures, and why it needs a partner test

PRA reflects both the amount of renin present and the availability of its substrate, angiotensinogen. DRC measures renin mass alone. That distinction has practical consequences: oral estrogen raises angiotensinogen, which can inflate PRA readings without any real change in renin secretion, an effect that does not occur with DRC assays, as noted in endocrinology literature on assay differences. The 2016 Endocrine Society guideline accepts either method for ARR screening but requires each laboratory to set its own assay-specific cutoff rather than relying on a universal number.

A suppressed PRA of, say, 0.1 ng/mL/hr could reflect primary aldosteronism, chronic volume overload from ordinary salt-sensitive hypertension, or a delayed-processing artifact. Aldosterone is what resolves that ambiguity, which is why the two tests are ordered together rather than sequentially.

Serum aldosterone: the test that makes PRA interpretable

Aldosterone paired with PRA, expressed as the ARR, is the screening tool recommended by the Endocrine Society and the American Association of Clinical Endocrinologists for primary aldosteronism. A commonly used threshold is an ARR above 30 (ng/dL per ng/mL/hr) with a concurrent aldosterone level of 10 ng/dL or higher, though exact cutoffs are lab-dependent and should not be treated as universal.

Subtype-specific treatment guided by paired aldosterone and renin testing, followed by adrenalectomy in lateralized disease, has been reported in observational surgical cohorts to produce complete biochemical success in a large majority of patients at 12 months, based on the largest prospective outcomes dataset in this area. That figure describes outcomes after surgery in a selected, lateralized surgical population, not the general hypertensive population being screened.

Both samples should come from the same visit, ideally between 0800 and 1000, after the patient has been upright for at least two hours and seated for 5 to 15 minutes immediately before the draw. The Endocrine Society guideline treats the ARR as the preferred screening approach and recommends applying it broadly among patients with hypertension who have features suggesting secondary causes.

Basic metabolic panel: potassium, sodium, and kidney function

Potassium should be measured with PRA and corrected toward normal before the ARR is interpreted. Hypokalemia stimulates renin secretion on its own, independent of the renin-angiotensin-aldosterone axis, which can raise PRA enough to mask the suppressed renin that characterizes primary aldosteronism.

In a cross-sectional cohort of patients referred for suspected primary aldosteronism, a substantial share had hypokalemia at the time of screening, and false-negative ARR results were more common among those with lower potassium at draw, according to a small observational cohort. The practical takeaway is not a specific percentage to memorize but a rule: do not trust an ARR drawn during uncorrected hypokalemia.

Sodium adds context. A high-normal or elevated sodium alongside suppressed PRA and elevated aldosterone strengthens suspicion for mineralocorticoid excess. Low sodium with elevated PRA points toward secondary causes of renin elevation, such as renal artery stenosis, diuretic effect, or heart failure.

Creatinine or estimated GFR should be included because advanced chronic kidney disease alters the renin-angiotensin-aldosterone axis in ways that make ARR interpretation less reliable; guideline documents generally flag reduced reliability at an eGFR below roughly 30 mL/min/1.73 m².

Morning cortisol: ruling out overlapping glucocorticoid excess

Primary aldosteronism and Cushing syndrome can present similarly, with hypertension, hypokalemia, and metabolic derangement overlapping between the two. Missing cortisol excess while pursuing an aldosterone diagnosis delays correct treatment, which is why a morning cortisol, or in ambiguous cases a 1 mg overnight dexamethasone suppression test, is a reasonable companion test rather than an automatic requirement for every patient.

A retrospective cohort of patients referred for adrenal incidentaloma found that a meaningful minority had subclinical hypercortisolism coexisting with an abnormal ARR, and this group is thought in small retrospective series to carry a worse cardiovascular risk profile than patients with either abnormality alone. Endocrine society guidance on adrenal incidentalomas generally recommends screening for both cortisol and aldosterone excess whenever an adrenal nodule is found, rather than assuming a single hormonal cause.

As a rough interpretive frame from the Endocrine Society Cushing syndrome guideline: a single morning cortisol below about 5 mcg/dL generally argues against Cushing syndrome, and values above about 15 mcg/dL are usually reassuring, but the gray zone between those numbers warrants formal suppression testing rather than a same-day conclusion.

A decision framework: what to order alongside PRA, by clinical scenario

The right paired panel depends on why PRA is being ordered in the first place, what medications the patient is on, and whether an adrenal finding is already in play. This framework organizes the common scenarios into a single reference.

The common failure mode across all six rows is the same: ordering PRA and aldosterone correctly but drawing them under conditions (wrong posture, wrong time of day, uncorrected potassium, active interfering medication) that make the ratio meaningless. Getting the test list right does not substitute for getting the draw conditions right.

Thyroid panel and metanephrines: completing a secondary hypertension workup

For patients under 40 with new-onset hypertension, or anyone with resistant hypertension, a fuller secondary-hypertension panel is reasonable beyond renin and aldosterone. That typically adds TSH, free T4, and fractionated plasma metanephrines, reflecting a broader recognition in scientific statements on resistant hypertension that treatable secondary causes are disproportionately represented in this population.

Pheochromocytoma is uncommon in unselected hypertensive patients but more concentrated among those with resistant hypertension, and the Endocrine Society pheochromocytoma guideline reports fractionated plasma metanephrines carry high sensitivity for the diagnosis when drawn supine after a rest period, which minimizes false-positive normetanephrine elevations from sympathetic activation at the draw itself 10.

TSH screens for thyroid contributions to blood pressure: hyperthyroidism raises cardiac output and lowers vascular resistance, producing systolic hypertension, while hypothyroidism tends to raise diastolic pressure through increased peripheral resistance. A clinical review of the incidentally discovered adrenal mass argues that clinicians who skip secondary-cause screening in resistant hypertension will miss treatable, sometimes curable, conditions in a meaningful share of that population; the exact proportion is better sourced from the AHA statement above than from a single narrative review, and readers should treat any specific percentage from either source as an estimate rather than a fixed rate.

Medication adjustments before testing

Several common antihypertensives distort PRA and aldosterone enough to invalidate ARR screening, so the medication hold protocol matters as much as which tests are ordered.

Mineralocorticoid receptor antagonists (spironolactone, eplerenone) should generally be stopped at least four weeks before ARR screening because they raise both PRA and aldosterone and can distort the ratio in either direction depending on the patient's underlying physiology. Beta-blockers suppress renin and can produce a falsely elevated ARR even with normal aldosterone. ACE inhibitors and ARBs raise PRA through feedback disinhibition and can normalize an otherwise abnormal ratio. Diuretics stimulate renin through volume depletion.

The Endocrine Society guideline suggests transitioning patients to agents with minimal renin-angiotensin-aldosterone effect, such as verapamil (sustained release) and doxazosin, during the washout period when blood pressure control cannot be paused entirely, per commonly cited endocrine society guidance. Specific dosing decisions belong to the prescribing clinician managing the individual patient's blood pressure and comorbidities; this article does not set a dose.

For patients who cannot safely stop a beta-blocker, for example those with heart failure with reduced ejection fraction or a recent myocardial infarction, the clinician should document the medication on the lab order and interpret a suppressed PRA with the possibility that it is pharmacologic rather than pathologic.

Confirmatory testing after a positive ARR screen

A positive ARR is a screening result. It is not a diagnosis, and it should not by itself trigger adrenal CT or adrenal vein sampling. Guideline sources generally accept four confirmatory protocols:

Oral sodium loading test. The patient consumes a high-sodium diet for three days, then collects a 24-hour urine on day three to measure aldosterone, sodium, and creatinine. An elevated urinary aldosterone alongside confirmed adequate sodium loading supports the diagnosis.

Intravenous saline infusion test. A defined volume of normal saline is infused over several hours, and a plasma aldosterone that fails to suppress afterward supports autonomous secretion. This test is avoided in patients with uncontrolled heart failure.

Fludrocortisone suppression test. The patient receives fludrocortisone with sodium and potassium supplementation over several days, with aldosterone and renin checked on the final day. This is considered the most sensitive option but requires inpatient monitoring.

Captopril challenge. Aldosterone is measured before and after a single oral dose of captopril. Failure of aldosterone to suppress meaningfully supports the diagnosis. This is the simplest outpatient option.

A separate line of evidence concerns how to choose between adrenal vein sampling (AVS) and CT imaging for lateralizing confirmed disease before surgery. The SPARTACUS trial compared CT-based management with AVS-guided management and is frequently cited for a noninferiority finding. The citation available in the source material for this trial could not be independently confirmed against the correct PubMed identifier in this draft, so the specific outcome numbers require verification against the primary SPARTACUS publication before they are stated as fact. What is established without dispute is that AVS remains the guideline-preferred method for lateralization in patients being considered for surgery, per widely cited endocrine society guidance.

Reading high, low, and normal PRA

Normal range. PRA in a seated, salt-replete adult commonly falls around 0.25 to 5.82 ng/mL/hr, but reference ranges vary by assay and laboratory, and results should always be read against the reporting lab's specific interval rather than a number memorized from elsewhere.

High PRA points toward secondary hyperaldosteronism or a non-aldosterone cause of renin elevation: renal artery stenosis, dehydration, chronic diuretic use, heart failure, or ACE inhibitor/ARB therapy. High PRA with high aldosterone suggests secondary hyperaldosteronism. High PRA with normal or low aldosterone can reflect ACE inhibitor or ARB use, or an adrenal insufficiency state.

Low PRA combined with high aldosterone is the classic pattern in primary aldosteronism. Low PRA with low aldosterone suggests mineralocorticoid excess from a non-aldosterone source, such as licorice ingestion, Liddle syndrome, congenital adrenal hyperplasia from 11-beta-hydroxylase deficiency, or exogenous fludrocortisone.

The Endocrine Society guideline frames the core clinical point plainly: a suppressed renin found in the context of hypertension should prompt paired aldosterone measurement rather than being written off as a normal variant.

PRA is not itself a treatment target

PRA is a physiologic marker, not something clinicians treat directly. The goal is to treat the underlying condition that produced the abnormal value, not to chase the number.

For high PRA from volume depletion, correcting dehydration, adjusting diuretic dosing, and reviewing sodium intake are the relevant levers. In renovascular hypertension with high PRA, revascularization or ACE-inhibitor-based medical management may be appropriate depending on the individual case; a large randomized trial of renal artery stenting found that routine stenting did not outperform medical therapy alone for most patients with atherosclerotic renal artery stenosis, which argues against reflexive revascularization.

For low PRA from primary aldosteronism, unilateral adrenalectomy in lateralized disease is associated with high biochemical cure rates in large observational cohorts, though hypertension cure (as opposed to biochemical cure) was reported in a minority of patients at long-term follow-up. For bilateral disease, or patients who are not surgical candidates, mineralocorticoid receptor antagonists are first-line medical therapy; specific starting doses and titration are individualized decisions for the treating clinician and are not provided here.

Dietary sodium restriction supports blood pressure control broadly. The DASH-Sodium trial found a substantial mean reduction in systolic blood pressure when sodium intake was lowered from a high to a low level among hypertensive participants, though that trial was not designed around renin or aldosterone status and its findings should not be read as specific to primary aldosteronism 14.

Pre-analytic variables that make results uninterpretable

PRA is one of the more pre-analytically sensitive common lab tests, and controlling for posture, timing, specimen handling, and dietary sodium matters as much as ordering the right panel.

Posture. PRA rises several-fold from supine to upright. Guideline sources recommend the patient be seated for 5 to 15 minutes before the draw; drawing while supine can lower PRA and produce a falsely elevated ARR.

Time of day. Renin and aldosterone follow a circadian pattern peaking in the early morning, so draws are typically scheduled between 0800 and 1000 to match published reference ranges.

Specimen handling. PRA samples should be collected in chilled EDTA tubes and centrifuged promptly under refrigeration. Specimens left at room temperature can generate angiotensin I after the draw, falsely elevating PRA. Some laboratories favor DRC assays partly because they are thought to be less vulnerable to this kind of handling error.

Dietary sodium. Very low sodium intake can stimulate renin strongly enough to normalize the ARR in a patient who actually has primary aldosteronism, producing a false negative. A same-day or recent 24-hour urine sodium helps confirm whether the patient was on an adequate salt intake at the time of testing.

Getting the draw conditions wrong is at least as common a source of error as ordering the wrong panel. A correctly chosen set of tests collected under the wrong conditions still produces data that cannot be interpreted.

What is established, what is plausible, and what is not established

Established: the ARR built from paired PRA (or DRC) and aldosterone is the guideline-recommended screening approach for primary aldosteronism, and a positive screen requires confirmatory testing before proceeding to imaging or adrenal vein sampling. Established: potassium correction, posture, draw timing, and interfering medications materially affect ARR validity.

Plausible but unproven at the level of a firm rule: universal numeric cutoffs for ARR positivity, since the guideline itself defers to lab-specific validation rather than a single threshold. Precise outcome statistics quoted from individual cohort or trial reports (for example biochemical cure rates after adrenalectomy) describe the specific populations studied and should not be generalized to all patients with an abnormal ARR.

Not established from the material available here: the exact comparative outcome numbers from the SPARTACUS trial, which require verification against the primary publication before being cited as fact, and any claim about the precise population-wide share of resistant hypertension attributable to secondary causes, which varies across the cited sources and should be treated as an estimate rather than a fixed figure.

This article is educational and does not provide individualized diagnosis, dosing, or medication-change instructions. Anyone with symptoms of an adrenal crisis, severe uncontrolled hypertension, chest pain, or new neurological symptoms should seek urgent medical care rather than waiting on lab results.